U.S. Markets open in 3 hrs 36 mins

Dermapharm Holding SE (DMP.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
86.90+0.70 (+0.81%)
As of 11:33AM CEST. Market open.

Dermapharm Holding SE

Lil-Dagover-Ring 7
Grünwald 82031
49 89 6 41 86 0

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees2,311

Key Executives

NameTitlePayExercisedYear Born
Dr. Hans-George FeldmeierCEO & Chairman of the Management BoardN/AN/AN/A
Ms. Hilde NeumeyerCFO, Chief Compliance Officer & Member of the Management BoardN/AN/AN/A
Ms. Karin SamuschMember of the Management Board & Chief Bus. Devel. OfficerN/AN/AN/A
Dr. Jürgen OttChief Marketing Officer & Member of Management BoardN/AN/A1969
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the Hübner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. Dermapharm Holding SE has partnership with CORAT Therapeutics GmbH for the development of COR-101. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

Corporate Governance

Dermapharm Holding SE’s ISS Governance QualityScore as of July 1, 2021 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.